Elevated Levels of Eotaxin-2 in Serum of Fibromyalgia Patients

Abstract EN

FMS patients demonstrate an altered profile of chemokines relative to healthy controls (HC).

Eotaxin-2 is a potent chemoattractant distributed in a variety of tissues.

The aim of the study was to compare serum levels of eotaxin-2 between FMS patients and HC and to examine a potential correlation between eotaxin-2 levels and clinical parameters of FMS.

Methods.

50 patients with FMS and 15 HC were recruited.

Data on the severity of FMS symptoms and depression were collected.

Serum levels of eotaxin-2 (ELISA) were determined in all participants.

High-sensitive CRP (hs-CRP) was measured in the FMS group.

Results.

The FMS cohort included predominantly females (84%), mean age of 49, and mean disease duration of 6 years.

FMS patients exhibited significantly higher eotaxin-2 levels (pg/ml) versus HC: 833 (±384) versus 622 (±149), p=0.04.

Mean hs-CRP level among FMS patients was 4.8 ± 6 mg/l, a value not indicative of acute inflammation.

No correlation was found between eotaxin-2 and hs-CRP levels.

No correlation was found between eotaxin-2 and severity measures of FMS or depression.

Conclusion.

Eotaxin-2 does not appear to be a candidate for a disease activity biomarker in FMS.

Further research is warranted into the role of this chemokine in the pathophysiology of the FMS.